臨床婦人科産科76巻11号

2022年11月発行

今月の臨床 生殖医療の安全性―どんなリスクと留意点があるのか？ 患者に対する安全性

OHSSとその予防・治療

著者： 黄海鵬¹ 髙井泰¹

所属機関： ¹埼玉医科大学総合医療センター産婦人科

ページ範囲：P.1067 - P.1076

●卵巣過剰刺激症候群（OHSS）は排卵誘発薬により発症する医原性疾患である．不妊治療の保険診療化による若年層の需要増に伴い，OHSS発症数が増えることも懸念される．

●卵巣腫大，腹水および胸水の貯留，血液濃縮などを呈し，血栓塞栓症や多臓器不全などにより危機的状態に陥る可能性もある．重症度分類を正しく行い，推奨された適切な管理を行うことが求められる．

●さまざまなOHSS予防策を保険診療の範囲内で講じていく必要がある．

参考文献

1）令和2年度倫理委員会登録・調査小委員会報告（委員長 : 片桐由起子）．日産婦誌73 : 1089-1100, 2021

2）日本生殖医学会（監修・編） : 生殖医療ガイドライン．日本生殖医学会，2021

3）日本産科婦人科学会，他（編） : 卵巣過剰刺激症候群（OHSS）の発症や重症化の予防は？　産婦人科診療ガイドライン―婦人科外来編2020．pp205-208，日本産科婦人科学会事務局，2020.

4）生殖・内分泌委員会報告．卵巣過剰刺激症候群の管理方針と防止のための留意事項．日産婦誌61 : 1138-1145, 2009

5）厚生労働省 : 重篤副作用疾患別対応マニュアル 卵巣過剰刺激症候群（OHSS）．https://h-crisis.niph.go.jp/wp-content/uploads/2020/09/20200902104616_content_11121000_000665767.pdf

6）Geva E, et al : Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74 : 429-438, 2000

7）Pellicer A, et al : The pathogenesis of ovarian hyperstimulation syndrome : in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71 : 482-489, 1999

8）Neulen J, et al : Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells : importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80 : 1967-1971, 1995

9）福井淳史，他 : 【不妊治療の実際】不妊治療とOHSS（卵巣過剰刺激症候群）．産婦治療87 : 36-42, 2003

10）高井　泰 : 【不妊治療ハンドブック】治療 OHSSの予防と対策．産婦の実際58 : 1753-1760, 2009

11）Petrenko AP, et al : Ovarian hyperstimulation syndrome. A new look at an old problem. Gynecol Endocrinol 35 : 651-656, 2019

12）Kuroda K, et al : Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals. Reprod Biomed Online 42 : 125-132, 2001

13）Katagiri Y, et al : Assisted reproductive technology in Japan : a summary report for 2019 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. Reprod Med Biol 21 : e12434, 2021

14）日本生殖医学会（編・監修） : 卵巣過剰刺激症候群の予防・治療．生殖医療の必修知識2020．pp435-444，日本生殖医学会，2020

15）Schirmer DA 3rd, et al : Ovarian hyperstimulation syndrome after assisted reproductive technologies : trends, predictors, and pregnancy outcomes. Fertil Steril 114 : 567-578, 2020

16）Asada Y, et al : Age-specific serum anti-Mullerian hormone concentration in Japanese women and its usefulness as a predictor of the ovarian response. Reprod Med Biol 16 : 364-373, 2017

17）Lee TH, et al : Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 23 : 160-167, 2008

18）Ocal P, et al : Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 28 : 1197-1203, 2011

19）Jayaprakasan K, et al : Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 98 : 657-663, 2012

20）Zech J, et al : Elective frozen-thawed embryo transfer（FET）in women at risk for ovarian hyperstimulation syndrome. Reprod Biol 18 : 46-52, 2018

21）Cui L, et al : Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology : a systematic review and meta-analysis. Arch Gynecol Obstet 303 : 615-630, 2021

22）Mai Q, et al : Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women : a prospective randomized trial. Am J Obstet Gynecol 216 : 42.e1-42.e10, 2017

23）Haas J, et al : The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle. Reprod Biol Endocrinol 16 : 54, 2018

24）Zhao J, et al : Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. Reprod Health 17 : 181, 2020

25）Vembu R, et al : Serum AMH level to predict the hyper response in women with PCOS and Non-PCOS undergoing controlled ovarian stimulation in ART. J Hum Reprod Sci 10 : 91-94, 2017

26）Tso LO, et al : Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 12 : CD006105, 2020

27）Bordewijk EM, et al : Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2 : CD001122, 2020

28）Ishihara O, et al : Randomized, assessor-blind, antimullerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil Steril 115 : 1478-1486, 2021

29）Ishihara O, et al : Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients : a randomized controlled trial. Reprod Biomed Online 42 : 909-918, 2021

30）Jayaprakasan K, et al : Estimating the risks of ovarian hyperstimulation syndrome（OHSS）: implications for egg donation for research. Hum Fertil（Camb） 10 : 183-187, 2007

31）Practice Committee of the American Society for Reproductive Medicine : Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome : a guideline. Fertil Steril 106 : 1634-1647, 2016

32）Whelan JG 3rd, et al : The ovarian hyperstimulation syndrome. Fertil Steril 73 : 883-896, 2000

33）Youssef MA, et al : Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev（10） : CD008046, 2014

34）Bourdon M, et al : GnRHa（alone or combined with hCG） versus hCG alone for ovulation triggering during controlled ovarian stimulation for IVF/ICSI : a systematic review and meta-analysis. F&S Reviews 2 : 353-370, 2021

35）Tang H, et al : Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 11 : CD008605, 2016

36）Soares SR, et al : Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14 : 321-333, 2008

37）Tang H, et al : Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev ; 4 : CD008605, 2021

38）厚生労働省保険局医療課 : 不妊治療に係る診療報酬上の取扱いについて．2022年3月16日　https://www.mhlw.go.jp/content/12404000/000913723.pdf

39）柴原浩章，他 : 【女性診療科医のための薬物療法マニュアル】婦人科の薬物療法 生殖・不妊・避妊 卵巣過剰刺激症候群．産婦治療86 : 667-674, 2003

40）Sennström M, et al : Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand 96 : 1045-1052, 2017